Reaching consensus on drug resistance conferring mutations

Daniela M Cirillo; Paolo Miotto; Elisa Tagliani; ReSeqTB Consortium

doi:10.1016/j.ijmyco.2016.09.062

Reaching consensus on drug resistance conferring mutations

Int J Mycobacteriol. 2016 Dec:5 Suppl 1:S31-S32. doi: 10.1016/j.ijmyco.2016.09.062. Epub 2016 Nov 15.

Authors

Daniela M Cirillo¹, Paolo Miotto², Elisa Tagliani²; ReSeqTB Consortium²

Affiliations

¹ Emerging Bacterial pathogens Unit, San Raffaele Scientific Institute, via Olgettina 60, Milan, Italy. Electronic address: danielamariacirillo5@gmail.com.
² Emerging Bacterial pathogens Unit, San Raffaele Scientific Institute, via Olgettina 60, Milan, Italy.

PMID: 28043595
DOI: 10.1016/j.ijmyco.2016.09.062

Abstract

Objective/background: Molecular-based, rapid drug-susceptibility tests are needed to guide the appropriate use of new drugs and new therapeutic regimens at the programmatic level, and to prevent a further increase in the incidence of drug-resistant tuberculosis (TB). Experts have recognized the need for a global, curated, and standardized analysis and data-sharing platform that provides a one-stop data source for clinically relevant genotypic and phenotypic information on Mycobacterium tuberculosis.

Methods: To this purpose, the Relational Sequencing TB Data Platform (ReSeqTB) consortium has critically reviewed the most inclusive set of published data on mutations associated with drug resistance in M. tuberculosis to date, and has graded a comprehensive list of globally prevalent mutations based on the strength of their association with drug resistance.

Results and conclusions: ReSeqTB serves as a single repository for the compilation, curation, and validation of existing and newly created sequences and metadata on M. tuberculosis strains and will use the currently reviewed data set, validated by international experts, as a starting point until sufficient new sequence data are accumulated. This initiative is supported by a global partnership of academic institutions, public health agencies, and nongovernmental organizations including the Critical Path Institute, FIND, the World Health Organization, the New Diagnostics Working Group, the U.S. Centers for Disease Control and Prevention, and the National Institute of Allergy and Infectious Diseases and it is financially supported by the Bill & Melinda Gates Foundation. Key strengths of the ReSeqTB Database include the following:Successful execution of such an extensive database platform requires substantial collaboration from scientists investigating the genetic basis for drug resistance worldwide, and from developers with expertise in database design and implementation.

Keywords: Conferring mutations; Drug resistance; Molecular-based; Rapid drug-susceptibility tests.